Stifel Nicolaus Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $16.00

Elanco Animal Health (NYSE:ELAN) had its price target trimmed by Stifel Nicolaus from $18.00 to $16.00 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ELAN has been the topic of a number of other research reports. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 target price on the stock. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Finally, Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $11.02 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a 50-day moving average of $11.80 and a two-hundred day moving average of $13.10. The stock has a market cap of $5.45 billion, a P/E ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 1-year low of $10.77 and a 1-year high of $18.80.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the company. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $29,000. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC increased its stake in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.